0001752724-23-099451.txt : 20230512 0001752724-23-099451.hdr.sgml : 20230512 20230512172252 ACCESSION NUMBER: 0001752724-23-099451 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 EFFECTIVENESS DATE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JPMorgan Institutional Trust CENTRAL INDEX KEY: 0001303608 IRS NUMBER: 201491791 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-21638 FILM NUMBER: 23917122 BUSINESS ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 BUSINESS PHONE: 800-480-4111 MAIL ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 0001303608 S000007336 JPMorgan Intermediate Bond Trust C000020140 JPMorgan Intermediate Bond Trust 0001303608 S000007337 JPMorgan Core Bond Trust C000020141 JPMorgan Core Bond Trust 0001303608 S000007338 JPMorgan Equity Index Trust C000020142 JPMorgan Equity Index Trust N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0001303608 XXXXXXXX 811-21638 true false false N-1A true JPMorgan Institutional Trust 811-21638 0001303608 5493005FRK56SHN6MJ34 277 Park Avenue New York 10172 US-NY US 800-480-4111 JPMorgan Chase Bank, N.A. 383 Madison Avenue New York 10179 212-270-6000 Records relating to its functions as sub-administrator and fund accounting agent JPMorgan Chase Bank, N.A. 4 Chase Metrotech Center Brooklyn 11245 718-242-0609 Records relating to its functions as custodian J.P. Morgan Investment Management Inc. 383 Madison Avenue New York 10179 800-343-1113 Records relating to its functions as investment adviser and administrator J.P. Morgan Institutional Investments, Inc. 383 Madison Avenue New York 10179 201-595-1958 Records relating to its functions as placement agent DST Asset Manager Solutions, Inc. 2000 Old Colony Drive Quincy 02169 617-483-5000 Records relating to its functions as transfer agent N N N-1A 2 N Robert J. Grassi 006093150 N Raymond Kanner N/A N Kathleen M. Gallagher N/A N Frankie D. Hughes N/A N Gary L. French N/A N Stephen P. Fisher N/A N Dr. Robert A. Oden, Jr. N/A N John F. Finn N/A N Marilyn McCoy N/A N Marian U. Pardo N/A N Mary E. Martinez N/A N Nina O. Shenker N/A Y Lawrence R. Maffia N/A N Robert E. Deutsch N/A Y Thomas P. Lemke N/A N Emily A. Youssouf N/A N Stephen M. Ungerman 002315698 277 Park Avenue New York 10172 XXXXXX N N N N N N JPMorgan Distribution Services, Inc. 8-52700 000104234 N/A Y N PricewaterhouseCoopers LLP 238 5493002GVO7EO8RNNS37 N N N N N N N JPMorgan Core Bond Trust S000007337 549300Q7485FUJKEMM46 N 0 0 0 N/A N N Y N Citibank N.A. E57ODZWZ7FF32TWEFA76 N N Revenue sharing split Cash collateral reinvestment fee 0.00000000 0.00000000 Rule 32a-4 (17 CFR 270.32a-4) Rule 10f-3 (17 CFR 270.10f-3) Rule 12d1-4 (17 CFR 270.12d1-4) Rule 18f-4(f)(17 CFR 270.18f-4(f)) Rule 18f-4 (17 CFR 270.18f-4) Rule 12d1-1 (17 CFR 270.12d1-1) Y Y N N J.P. Morgan Investment Management Inc. 801-21011 000107038 549300W78QHV4XMM6K69 N DST Asset Manager Solutions, Inc. 84-00896 N/A N N N Bloomberg L.P. 549300B56MD0ZC402L06 N ICE Data Pricing & Reference Data, LLC 5493000NQ9LYLDBCTL34 N PricingDirect Inc. 549300WIC0TOJ7N7GD54 Y Refinitiv Global Markets Inc. 000109120 CRD N Y JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y N Self - rule 17f-2 (17 CFR 270.17f-2) BofA Securities, Inc. 549300HN4UKV1E2R3U73 N Y Futures commission merchants and commodity clearing organizations - rule 17f-6 (17 CFR 270.17f-6) N N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y Y J.P. Morgan Investment Management Inc. 549300W78QHV4XMM6K69 Y N N Deutsche Bank Securities Inc. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 748.80000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 2286.05000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 783.30000000 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 1848.00000000 Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 493.60000000 6159.75000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 51613818.38000000 Wells Fargo Securities, LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 479160085.05000001 Credit Suisse Securities (USA) LLC 8-00422 000000816 1V8Y6QCX6YMJ2OELII46 49129181.60999999 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 284050808.79000002 Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 405951453.08999997 BofA Securities, Inc. 8-69787 000283942 549300HN4UKV1E2R3U73 392700940.94000000 Brean Capital, LLC 8-40742 000023723 254900ZZA1UBVDCNQ378 34892472.03000000 BNP Paribas Securities Corp. 8-32682 000015794 RCNB6OTYUAMMP879YW96 66716895.92000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 70710382.46999999 RBC Capital Markets, LLC 8-45411 000031194 549300LCO2FLSSVFFR64 34769964.67000000 2175969162.44999980 N 2038770121.72000000 Uncommitted 100000000.00000000 N Committed 1500000000.00000000 N N N N JPMorgan Intermediate Bond Trust S000007336 5493001V1VDT1J53V683 N 0 0 0 N/A N N Y N Citibank N.A. E57ODZWZ7FF32TWEFA76 N N Cash collateral reinvestment fee Revenue sharing split 0.00000000 0.00000000 Rule 18f-4(f)(17 CFR 270.18f-4(f)) Rule 10f-3 (17 CFR 270.10f-3) Rule 22d-1 (17 CFR 270.22d-1) Rule 32a-4 (17 CFR 270.32a-4) Rule 12d1-4 (17 CFR 270.12d1-4) Rule 12d1-1 (17 CFR 270.12d1-1) Rule 18f-4 (17 CFR 270.18f-4) Y Y N N J.P. Morgan Investment Management Inc. 801-21011 000107038 549300W78QHV4XMM6K69 N DST Asset Manager Solutions, Inc. 84-00896 N/A N N N ICE Data Pricing & Reference Data, LLC 5493000NQ9LYLDBCTL34 N Bloomberg L.P. 549300B56MD0ZC402L06 N PricingDirect Inc. 549300WIC0TOJ7N7GD54 Y Y Credit Suisse Securities (USA) LLC 1V8Y6QCX6YMJ2OELII46 N Y Futures commission merchants and commodity clearing organizations - rule 17f-6 (17 CFR 270.17f-6) JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y N Self - rule 17f-2 (17 CFR 270.17f-2) N N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y Y J.P. Morgan Investment Management Inc. 549300W78QHV4XMM6K69 Y N N 0.00000000 Deutsche Bank Securities Inc. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 2470050.37000000 BofA Securities, Inc. 8-69787 000283942 549300HN4UKV1E2R3U73 2979086.80000000 Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 10806688.97000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 1316956.75000000 HSBC Securities (USA) Inc. 8-41562 000019585 CYYGQCGNHMHPSMRL3R97 709397.35000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 3499486.53000000 SG Americas Securities, LLC 8-66125 000128351 549300F35UE0BOM1WJ55 993288.32000000 BMO Nesbitt Burns Securities Ltd. 8-50538 000044057 M3LKFDNSJGJ7TMLH6Z15 CA 3347433.47000000 Wells Fargo Securities, LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 1680800.33000000 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 4765097.16000000 35871496.78000000 N 81481599.56000000 Uncommitted 100000000.00000000 N Committed 1500000000.00000000 N N N N false false true false false false INTERNAL CONTROL RPT 2 JPM_INSTT_Trust_IntCntrl_Ltr.htm HTML

Report of Independent Registered Public Accounting Firm

To the Board of Trustees of JPMorgan Institutional Trust and Shareholders of the funds listed in Appendix A

In planning and performing our audits of the financial statements of the funds listed in Appendix A (constituting JPMorgan Institutional Trust, hereafter collectively referred to as the “Funds”) as of and for the year ended February 28, 2023, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Funds’ internal control over financial reporting.

The management of the Funds is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Funds’ internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Funds’ internal control over financial reporting and their operations, including controls over safeguarding securities, that we consider to be material weaknesses as defined above as of February 28, 2023.

This report is intended solely for the information and use of the Board of Trustees of JPMorgan Institutional Trust and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.


/s/ PricewaterhouseCoopers LLP

New York, New York

April 26, 2023

Appendix A

JPMorgan Core Bond Trust

JPMorgan Intermediate Bond Trust